IGHE and cancer: However, 34 IgE-deficient patients with no malignancy diagnosis, identified in 2014–2015 and monitored for an average period of 43.5 months, showed incidences of malignancy significantly higher than non-IgE-deficient controls recruited during the same period/from the same hospital, and this outcome was independent from a diagnosis of CVID [58].